- Home
- ANIP
as 06-17-2025 4:00pm EST
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid-dose products. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended-release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. The company operates in two segments which include Rare Diseases and Brands, Generics, and Others. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.
| Founded: | 2001 | Country: | United States |
| Employees: | N/A | City: | BAUDETTE |
| Market Cap: | 1.3B | IPO Year: | N/A |
| Target Price: | $80.13 | AVG Volume (30 days): | 292.6K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.15 | EPS Growth: | N/A |
| 52 Week Low/High: | $52.50 - $77.00 | Next Earning Date: | 08-05-2025 |
| Revenue: | $674,068,000 | Revenue Growth: | 30.27% |
| Revenue Growth (this year): | 30.17% | Revenue Growth (next year): | 7.69% |
Stock Insider Trading Activity of ANI Pharmaceuticals Inc. (ANIP)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Cook Meredith | ANIP | SR. VP, GENERAL COUNSEL & SEC. | Jun 13 '25 | Sell | $61.37 | 400 | $24,548.00 | 79,345 | |
| Gutwerg Ori | ANIP | SVP, GENERICS | May 15 '25 | Sell | $60.07 | 881 | $52,921.67 | 89,897 | |
| Mutz Christopher | ANIP | HEAD OF RARE DISEASE | May 14 '25 | Sell | $60.45 | 4,000 | $241,800.00 | 107,317 | |
| Cook Meredith | ANIP | SR. VP, GENERAL COUNSEL & SEC. | May 13 '25 | Sell | $62.20 | 400 | $24,880.00 | 79,345 | |
| Shanmugam Muthusamy | ANIP | HEAD OF R&D, COO-NOVITIUM OPS | May 9 '25 | Sell | $76.83 | 700 | $53,781.00 | 631,920 | |
| Cook Meredith | ANIP | SR. VP, GENERAL COUNSEL & SEC. | Apr 14 '25 | Sell | $68.96 | 400 | $27,584.00 | 79,345 |
Latest ANI Pharmaceuticals Inc. News
ANIP Breaking Stock News: Dive into ANIP Ticker-Specific Updates for Smart Investing
StockStory
2 days ago
3 of Wall Street’s Favorite Stocks with Questionable Fundamentals
GlobeNewswire
6 days ago
ANI Pharmaceuticals Announces Presentation of New Preclinical Data
StockStory
6 days ago
3 Healthcare Stocks with Mounting Challenges
StockStory
12 days ago
3 Cash-Producing Stocks in the Doghouse
StockStory
14 days ago
ANIP Q1 CY2025 Earnings Call: Generics, Rare Disease Drive Growth; Retina Headwinds Noted
GlobeNewswire
21 days ago
ANI Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference
StockStory
23 days ago
3 Reasons to Avoid ANIP and 1 Stock to Buy Instead
Clinical Trials Arena
a month ago
ANI Pharmaceuticals initiates Phase IV trial of gel for acute gout flares
Compare ANIP vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ANIP ANI Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.